What is the optimal treatment strategy for children with attention-deficit/hyperactivity disorder (ADHD) and comorbid anxiety, using dexmethylphenidate (Focalin) and dextroamphetamine (Dexedrine)?

Treatment of ADHD with Comorbid Anxiety in Children: Focalin vs Dexedrine

For children with ADHD and comorbid anxiety, FDA-approved stimulant medications (including both dexmethylphenidate/Focalin and dextroamphetamine/Dexedrine) are first-line treatment and should not be avoided due to anxiety concerns, as stimulants effectively treat both ADHD symptoms and often improve anxiety symptoms simultaneously. 1

Age-Specific Treatment Algorithm

For Children 6-12 Years Old

Start with either methylphenidate-based stimulants (including Focalin/dexmethylphenidate) or amphetamine-based stimulants (including Dexedrine/dextroamphetamine) as FDA-approved first-line agents 1. The 2019 AAP guidelines do not prioritize one stimulant class over another for this population with comorbid anxiety 1.

Key evidence: Early concerns that anxiety would worsen with stimulants or reduce treatment response have been definitively disproven. The landmark MTA study showed that children with ADHD and comorbid anxiety actually had greater treatment differences favoring stimulants compared to those without anxiety 2. Recent prospective studies confirm stimulants significantly improve both ADHD symptoms and anxiety symptoms, with reductions in generalized anxiety, separation anxiety, and school avoidance domains 3.

For Preschool Children (4-5 Years Old)

Methylphenidate formulations are recommended over dextroamphetamine (Dexedrine) for this age group 1. Although Dexedrine has FDA approval for children under 6 years, this approval predates modern stringent requirements, and evidence for dextroamphetamine in preschoolers is inadequate 1. Methylphenidate has moderate evidence from 269 children across multiple studies, though still used off-label 1.

Critical caveat: Only prescribe stimulants to preschoolers with moderate-to-severe ADHD after behavioral parent training has been attempted first 1.

Choosing Between Focalin and Dexedrine

Since guidelines do not differentiate between methylphenidate-based (Focalin) and amphetamine-based (Dexedrine) stimulants for school-age children with comorbid anxiety, the choice should be based on:

Individual Response Factors

• Trial both classes if needed: Children may respond better to one stimulant class than another despite equal population-level efficacy 4
• Titrate dosing: Maximal benefit requires dose adjustment and timing optimization (before breakfast, lunch, afternoon) 4

Practical Considerations for Focalin (Dexmethylphenidate)

• Rapid onset: Effects begin as early as 0.5 hours post-dose 5
• Duration: Extended-release formulation provides 11-12 hours of coverage 5
• Dosing flexibility: Capsules can be opened and sprinkled on applesauce for children who cannot swallow pills 5
• Lower insomnia risk: Recent real-world data shows SDX/d-MPH (related methylphenidate prodrug) associated with lower insomnia frequency compared to amphetamines 6

Practical Considerations for Dexedrine (Dextroamphetamine)

• Longer history of use: More established track record in clinical practice
• Alternative when methylphenidate fails: Provides mechanistically different option if Focalin ineffective

Managing Persistent Anxiety After Stimulant Initiation

If ADHD symptoms improve but anxiety remains problematic after adequate stimulant trial:

1. Add cognitive behavioral therapy (CBT) - This is strongly recommended and superior to medication alone for residual anxiety 7

2. Consider adjunctive SSRI for moderate-to-severe anxiety symptoms, with careful monitoring for side effects 2, 7

3. Alternative: Switch to atomoxetine - This non-stimulant shows impressive efficacy for both ADHD and anxiety symptoms, though not a first-line agent 7

4. Adjunctive alpha-agonists (extended-release guanfacine or clonidine) have FDA approval for combination with stimulants, though primarily studied for ADHD augmentation rather than anxiety 1

Critical Safety Monitoring

Both medications require monitoring for 8, 9:

• Cardiac screening: Check for heart defects or serious heart disease before starting; sudden death has occurred in patients with underlying cardiac conditions
• Blood pressure and heart rate: Monitor regularly during treatment
• Psychiatric symptoms: Watch for new/worsening behavioral problems, psychosis, or mania
• Growth parameters: Monitor height/weight in children on chronic treatment
• Abuse potential: Both are Schedule II controlled substances; assess risk before prescribing and monitor for misuse

Common pitfall to avoid: Do not withhold stimulant treatment due to presence of anxiety disorder. The evidence clearly shows stimulants are safe, well-tolerated, and often improve anxiety symptoms in this comorbid population 2, 3, 7.

Treatment Sequence

1. Initiate stimulant monotherapy (Focalin or Dexedrine based on factors above)
2. Titrate to optimal ADHD response over 2-6 weeks
3. Reassess anxiety symptoms at 6-12 weeks
4. Add anxiety-specific treatment only if needed (CBT first, then consider SSRI)

The presence of anxiety should not interfere with achieving full ADHD symptom control with stimulants 3.